Anti-cancer agent-induced nephrotoxicity

Anti-Cancer Agents in Medicinal Chemistry

Volumn 14, Issue 7, 2014, Pages 921-927

  Fukasawa, Hirotaka ^a   Furuya, Ryuichi ^a   Yasuda, Hideo ^b   Yamamoto, Tatsuo ^c   Hishida, Akira ^d   Kitagawa, Masatoshi ^b  

^a Iwata City Hospital   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Numazu City Hospital   (Japan)

^d University of Tokyo   (Japan)

Author keywords

Acute kidney injury; Anti cancer agents; Chemotherapy; Cisplatin; Electrolyte abnormality; Nephrotoxicity

Indexed keywords

ANTINEOPLASTIC AGENT;

CHEMICALLY INDUCED; HUMAN; KIDNEY DISEASES; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANTINEOPLASTIC AGENTS; HUMANS; KIDNEY DISEASES; THROMBOTIC MICROANGIOPATHIES;

EID: 84905642432     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520614666140127105809     Document Type: Review

References (101)

1. Kintzel, P.E. Anticancer drug-induced kidney disorders. Drug Saf., 2001, 24(1), 19-38.
2. Janssen-Heijnen, M.L.; Maas, H.A.; Houterman, S.; Lemmens, V. E.; Rutten, H.J.; Coebergh J.W. Comorbidity in older surgical cancer patients: Influence on patient care and outcome. Eur. J. Cancer, 2007, 43(15), 2179-2193.
3. Davies, D.F.; Shock, N.W. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J. Clin. Invest., 1950, 29(5), 496-507.
4. Sahni, V.; Choudhury, D.; Ahmed, Z. Chemotherapy-associated renal dysfunction. Nat. Rev. Nephrol., 2009, 5(8), 450-462.
5. Perazella, M.A.; Moeckel, G.W. Nephrotoxicity from chemotherapeutic agents: Clinical manifestations, pathobiology, and prevention/ therapy. Semin. Nephrol., 2010, 30(6), 570-581.
6. Lameire, N.; Kruse, V.; Rottey, S. Nephrotoxicity of anticancer drugs--an underestimated problem? Acta Clin. Belg., 2011, 66(5), 337-345.
7. Einhorn, L.H.; Williams, S.D. The role of cis-platinum in solid-tumor therapy. N. Engl. J. Med., 1979, 300(6), 289-291.
8. Arany, I.; Safirstein, R.L. Cisplatin nephrotoxicity. Semin. Nephrol., 2003, 23(5), 460-464.
9. Hartmann, J.T.; Lipp, H.P. Toxicity of platinum compounds. Exp. Opin. Pharmacother., 2003, 4(6), 889-901.
10. Safirstein, R.; Miller P.; Guttenplan J.B. Uptake and metabolism of cisplatin by rat kidney. Kidney Int., 1984, 25(5), 753-758.
11. Yao, X.; Panichpisal, K.; Kurtzman, N.; Nugent, K. Cisplatin nephrotoxicity: A review. Am. J. Med. Sci., 2007, 334(2), 115-124.
12. Endo, T.; Kimura O.; Sakata M. Carrier-mediated uptake of cisplatin by the OK renal epithelial cell line. Toxicology, 2000, 146(2-3), 187-195.
13. Kolb, R.J.; Ghazi, A.M.; Barfuss, D.W. Inhibition of basolateral transport and cellular accumulation of cDDP and N-acetyl-L-cysteine-cDDP by TEA and PAH in the renal proximal tubule. Cancer Chemother. Pharmacol., 2003, 51(2), 132-138.
14. Ciarimboli, G.; Ludwig, T.; Lang, D.; Pavenstadt, H.; Koepsell, H.; Piechota, H.J.; Haier, J.; Jaehde, U.; Zisowsky, J.; Schlatter, E. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am. J. Pathol., 2005, 167(6), 1477-1484.
15. Filipski, K.K.; Loos, W.J.; Verweij, J.; Sparreboom, A. Interaction of Cisplatin with the human organic cation transporter 2. Clin. Cancer Res., 2008, 14(12), 3875-3880.
16. Ciarimboli, G.; Deuster, D.; Knief, A.; Sperling, M.; Holtkamp, M.; Edemir, B.; Pavenstadt, H.; Lanvers-Kaminsky, C.; am Zehnhoff-Dinnesen, A.; Schinkel, A.H.; Koepsell, H.; Jurgens, H.; Schlatter, E. Organic cation transporter 2 mediates cisplatin-induced oto-and nephrotoxicity and is a target for protective interventions. Am. J. Pathol., 2010, 176(3), 1169-1180.
17. Filipski, K.K.; Mathijssen, R. H.; Mikkelsen, T. S.; Schinkel, A. H.; Sparreboom, A. Contribution of organic cation transporter 2(OCT2) to cisplatin-induced nephrotoxicity. Clin. Pharmacol. Ther., 2009, 86(4), 396-402.
18. Ohta, K.Y.; Inoue, K.; Hayashi Y.; Yuasa H. Molecular identification and functional characterization of rat multidrug and toxin extrusion type transporter 1 as an organic cation/H+ antiporter in the kidney. Drug Metab. Dispos., 2006, 34(11), 1868-1874.
19. Terada, T.; Masuda, S.; Asaka, J.; Tsuda, M.; Katsura, T.; Inui, K. Molecular cloning, functional characterization and tissue distribution of rat H+/organic cation antiporter MATE1. Pharm. Res., 2006, 23(8), 1696-1701.
20. Nakamura, T.; Yonezawa, A.; Hashimoto, S.; Katsura, T.; Inui, K. Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem. Pharmacol., 2010, 80(11), 1762-1767.
21. Hartmann, J.T.; Kollmannsberger, C.; Kanz, L.; Bokemeyer, C. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int. J. Cancer, 1999, 83(6), 866-869.
22. Taguchi, T.; Nazneen, A.; Abid, M.R.; Razzaque, M.S. Cisplatin-associated nephrotoxicity and pathological events. Contrib. Nephrol., 2005, 148, 107-121.
23. Lajer, H.; Daugaard, G. Cisplatin and hypomagnesemia. CancerTreat. Rev., 1999, 25(1), 47-58.
24. Madias, N.E.; Harrington J. T. Platinum nephrotoxicity. Am. J. Med., 1978, 65(2), 307-314.
25. Stewart, D.J.; Dulberg, C.S.; Mikhael, N.Z.; Redmond, M.D.; Montpetit, V.A.; Goel, R. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother. Pharmacol., 1997, 40(4), 293-308.
26. De Jongh, F.E.; Verweij, J.; Loos, W.J.; De Wit, R.; De Jonge, M. J.; Planting, A.S.; Nooter, K.; Stoter, G.; Sparreboom, A. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J. Clin. Oncol., 2001, 19(17), 3733-3739.
27. Raj, G.V.; Iasonos, A.; Herr, H.; Donat, S.M. Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer. J. Clin. Oncol., 2006, 24(19), 3095-3100.
28. Gogas, H.; Shapiro, F.; Aghajanian, C.; Fennelly, D.; Almadrones, L.; Hoskins, W.J.; Spriggs, D.R. The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer. Gynecol. Oncol., 1996, 61(1), 22-26.
29. Cornelison, T.L.; Reed, E. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol. Oncol., 1993, 50(2), 147-158.
30. Santoso, J.T.; Lucci, J.A., Coleman, R.L.; Schafer, I.; Hannigan, E. V. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother. Pharmacol., 2003, 52(1), 13-18.
31. Safirstein, R.; Winston, J.; Moel, D.; Dikman, S.; Guttenplan, J. Cisplatin nephrotoxicity: Insights into mechanism. Int. J. Androl., 1987, 10(1), 325-346.
32. Daugaard, G. Cisplatin nephrotoxicity: Experimental and clinical studies. Dan. Med. Bull., 1990, 37(1), 1-12.
33. Hensley, M.L.; Hagerty, K.L.; Kewalramani, T.; Green D.M.; Meropol, N.J.; Wasserman, T.H.; Cohen, G.I.; Emami, B.; Gradishar, W.J.; Mitchell, R.B.; Thigpen, J.T.; Trotti, A.; Von Hoff, D.; Schuchter, L. M. American Society of Clinical Oncology 2008 clinical practice guideline update: Use of chemotherapy and radiation therapy protectants. J. Clin. Oncol., 2009, 27(1), 127-145.
34. Fung, M.C.; Storniolo, A.M.; Nguyen, B.; Arning, M.; Brookfield, W.; Vigil, J. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer, 1999, 85(9), 2023-2032.
35. Muller, S.; Schutt, P.; Bojko, P.; Nowrousian, M.R.; Hense, J.; Seeber, S.; Moritz, T. Hemolytic uremic syndrome following prolonged gemcitabine therapy: Report of four cases from a single institution. Ann. Hematol., 2005, 84(2), 110-114.
36. Michael, M.; Elliott, E.J.; Craig, J.C.; Ridley, G.; Hodson E.M. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: A systematic review of randomized controlled trials. Am. J. Kidney Dis., 2009, 53(2), 259-272.
37. Humphreys, B.D.; Sharman, J.P.; Henderson, J.M.; Clark, J.W.; Marks, P.W.; Rennke, H.G.; Zhu, A.X.; Magee, C.C. Gemcitabine-associated thrombotic microangiopathy. Cancer, 2004, 100(12), 2664-2670.
38. Glezerman, I.; Kris, M.G.; Miller, V.; Seshan, S.; Flombaum, C.D. Gemcitabine nephrotoxicity and hemolytic uremic syndrome: Report of 29 cases from a single institution. Clin. Nephrol., 2009, 71(2), 130-139.
39. Kaplan, A.A. Therapeutic apheresis for cancer related hemolytic uremic syndrome. Ther. Apher., 2000, 4(3), 201-206.
40. Von Baeyer, H. Plasmapheresis in thrombotic microangiopathy-associated syndromes: Review of outcome data derived from clinical trials and open studies. Ther. Apher., 2002, 6(4), 320-328.
41. Dirix, L.Y.; Van Oosterom, A.T. The role of ifosfamide in the treatment of sarcomas. Semin. Oncol., 1989, 16(1 Suppl 3), 39-45.
42. Tomita, N.; Kodama, F.; Kanamori, H.; Motomura, S.; Ishigatsubo, Y. Secondary central nervous system lymphoma. Int. J. Hematol., 2006, 84(2), 128-135.
43. Zamlauski-Tucker, M.J.; Morris, M.E.; Springate, J.E. Ifosfamide metabolite chloroacetaldehyde causes Fanconi syndrome in the perfused rat kidney. Toxicol. Appl. Pharmacol., 1994, 129(1), 170-175.
44. Skinner, R.; Pearson, A.D.; Price, L.; Coulthard, M.G.; Craft, A. W. Nephrotoxicity after ifosfamide. Arch. Dis. Child, 1990, 65(7), 732-738.
45. Skinner, R. Chronic ifosfamide nephrotoxicity in children. Med. Pediatr. Oncol., 2003, 41(3), 190-197.
46. Rossi, R.; Godde, A.; Kleinebrand, A.; Riepenhausen, M.; Boos, J.; Ritter, J.; Jurgens, H. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: Analysis of 120 patients. J. Clin. Oncol., 1994, 12(1), 159-165.
47. Dekkers, I.; Blijdorp, K.; Cransberg, K.; Pluijm, S.M.; Pieters R.; Neggers S.J.; Heuvel-Eibrink, M.M. Long-Term Nephrotoxicity in Adult Survivors of Childhood Cancer. Clin. J. Am. Soc. Nephrol., 2013,8(6),922-929.
48. Koch Nogueira, P.C.; Hadj-Aissa, A.; Schell, M.; Dubourg, L.; Brunat-Mentigny, M.; Cochat, P. Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma. Pediatr. Nephrol., 1998, 12(7), 572-575.
49. Loebstein, R.; Atanackovic, G.; Bishai, R.; Wolpin, J.; Khattak, S.; Hashemi, G.; Gobrial, M.; Baruchel, S.; Ito, S.; Koren, G. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children. J. Clin. Pharmacol., 1999, 39(5), 454-461.
50. Druker, B.J.; Talpaz, M.; Resta, D.J.; Peng, B.; Buchdunger, E.; Ford, J.M.; Lydon, N.B.; Kantarjian, H.; Capdeville, R.; Ohno-Jones, S.; Sawyers, C. L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 2001, 344(14), 1031-1037.
51. Peggs, K.; Mackinnon, S. Imatinib mesylate--the new gold standard for treatment of chronic myeloid leukemia. N. Engl. J. Med., 2003, 348(11), 1048-1050.
52. Demetri, G. D.; Von Mehren, M.; Blanke, C.D.; Abbeele, A.D.; Eisenberg, B.; Roberts, P.J.; Heinrich, M.C.; Tuveson, D.A.; Singer S.; Janicek M.; Fletcher J. A.; Silverman S. G.; Silberman S. L.; Capdeville, R.; Kiese, B.; Peng, B.; Dimitrijevic, S.; Druker, B. J.; Corless, C.; Fletcher, C.D.; Joensuu, H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med., 2002, 347(7), 472-480.
53. Cools, J.; DeAngelo, D.J.; Gotlib, J.; Stover, E.H.; Legare, R.D.; Cortes, J.; Kutok, J.; Clark, J.; Galinsky, I.; Griffin, J. D.; Cross, N. C.; Tefferi, A.; Malone, J.; Alam, R.; Schrier, S.L.; Schmid, J.; Rose, M.; Vandenberghe, P.; Verhoef, G.; Boogaerts, M.; Wlodarska, I.; Kantarjian, H.; Marynen, P.; Coutre, S.E.; Stone, R.; Gilliland, D.G. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med., 2003, 348(13), 1201-1214.
54. Nowell, P. C.; Hungerford, D.A. A minute chromosome in human granulocytic leukemia. Science, 1960, 132, 1497.
55. Rowley, J.D. Chromosomal patterns in myelocytic leukemia. N. Engl. J. Med., 1973, 289(4), 220-221.
56. Vandyke, K.; Fitter, S.; Dewar, A.L.; Hughes, T.P.; Zannettino, A. C. Dysregulation of bone remodeling by imatinib mesylate. Blood, 2010, 115(4), 766-774.
57. Kitiyakara, C.; Atichartakarn, V. Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571. Nephrol. Dial. Transplant., 2002, 17(4), 685-687.
58. Pou, M.; Saval, N.; Vera, M.; Saurina, A.; Sole, M.; Cervantes, F.; Botey, A. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. Leuk. Lymphoma, 2003, 44(7), 1239-1241.
59. Foringer, J.R.; Verani, R.R.; Tjia, V.M.; Finkel, K.W.; Samuels, J. A.; Guntupalli, J.S. Acute renal failure secondary to imatinib mesylate treatment in prostate cancer. Ann. Pharmacother., 2005, 39(12), 2136-2138.
60. Gafter-Gvili, A.; Ram, R.; Gafter, U.; Shpilberg, O.; Raanani, P. Renal failure associated with tyrosine kinase inhibitors--case report and review of the literature. Leuk. Res., 2010, 34(1), 123-127.
61. Takikita-Suzuki, M.; Haneda, M.; Sasahara, M.; Owada, M.K.; Nakagawa, T.; Isono, M.; Takikita, S.; Koya, D.; Ogasawara, K.; Kikkawa, R. Activation of Src kinase in platelet-derived growth factor-B-dependent tubular regeneration after acute ischemic renal injury. Am. J. Pathol., 2003, 163(1), 277-286.
62. Marcolino, M.S.; Boersma, E.; Clementino, N.C.; Macedo, A.V.; Marx-Neto, A.D.; Silva, M.H.; Van Gelder, T.; Akkerhuis, K.M.; Ribeiro, A.L. Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. Ann. Oncol., 2011, 22(9), 2073-2079.
63. Al Aly, Z.; Philoctete Ashley, J.M.; Gellens, M.E.; Gonzalez, E.A. Thrombotic thrombocytopenic purpura in a patient treated with imatinib mesylate: True association or mere coincidence? Am. J. Kidney Dis., 2005, 45(4), 762-768.
64. Francois, H.; Coppo, P.; Hayman, J.P.; Fouqueray, B.; Mougenot, B.; Ronco, P. Partial fanconi syndrome induced by imatinib therapy: A novel cause of urinary phosphate loss. Am. J. Kidney Dis., 2008, 51(2), 298-301.
65. Ianotto, J.C.; Tempescul, A.; Amet, Y.; Grall, P.; Dalbies, F.; Eveillard, J. R.; Guillerm, G.; Berthou, C. Imatinib mesylate induces massive and nonspecific aminoaciduria in CML patients. Am. J. Hematol., 2012, 87(4), 437-439.
66. Frei, E.; Jaffe, N.; Tattersall, M.H.; Pitman, S.; Parker, L. New approaches to cancer chemotherapy with methotrexate. N. Engl. J. Med., 1975, 292(16), 846-851.
67. Condit, P.T.; Chanes, R.E.; Joel, W. Renal toxicity of methotrexate. Cancer, 1969, 23(1), 126-131.
68. Weinblatt, M.E. Toxicity of low dose methotrexate in rheumatoid arthritis. J. Rheumatol. 1985, 12 Suppl 12, 35-39.
69. Widemann, B.C.; Balis, F.M.; Murphy, R.F.; Sorensen, J.M.; Montello, M.J.; O'Brien, M.; Adamson, P.C. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. J. Clin. Oncol., 1997, 15(5), 2125-2134.
70. Widemann, B.C.; Adamson, P.C. Understanding and managing methotrexate nephrotoxicity. Oncologist, 2006, 11(6), 694-703.
71. Molina, R.; Fabian, C.; Cowley, B., JR. Use of charcoal hemoperfusion with sequential hemodialysis to reduce serum methotrexate levels in a patient with acute renal insufficiency. Am. J. Med., 1987, 82(2), 350-352.
72. Anderson, D.R.; Grillo-Lopez, A.; Varns, C.; Chambers, K.S.; Hanna, N. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody(IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem. Soc. Trans., 1997, 25(2), 705-708.
73. Plosker, G.L.; Figgitt, D.P. Rituximab: A review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs, 2003, 63(8), 803-843.
74. Dimopoulos, M.A.; Alexanian, R.; Gika, D.; Anagnostopoulos, A.; Zervas, C.; Zomas, A.; Kyrtsonis, M.C.; Anagnostopoulos, N.; Pangalis, G.A.; Weber, D.M. Treatment of Waldenstrom's macroglobulinemia with rituximab: Prognostic factors for response and progression. Leuk. Lymphoma, 2004, 45(10), 2057-2061.
75. Ghobrial, I.M.; Fonseca, R.; Greipp, P.R.; Blood, E.; Rue, M.; Vesole, D.H.; Gertz, M.A. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: An Eastern Cooperative Oncology Group Study. Cancer, 2004, 101(11), 2593-2598.
76. Treon, S.P.; Branagan, A.R.; Hunter, Z.; Santos, D.; Tournhilac, O.; Anderson, K.C. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Ann. Oncol., 2004, 15(10), 1481-1483.
77. Shaikh, A.; Habermann, T.M.; Fidler, M.E.; Kumar, S.; Leung, N. Acute renal failure secondary to severe type I cryoglobulinemia following rituximab therapy for Waldenstrom's macroglobulinemia. Clin. Exp. Nephrol., 2008, 12(4), 292-295.
78. Izzedine, H.; Bourry, E.; Amrouche, L.; Brocheriou, I.; Uzunov, M.; Capron, F.; Leblond, V.; Deray, G. Immunoglobulin M 'Flare' after rituximab-associated acute tubular necrosis in Waldenstrom's macroglobulinemia. Int. J. Hematol., 2009, 89(2), 218-222.
79. Coussens, L.; Yang-Feng, T.L.; Liao, Y.C.; Chen, E.; Gray, A.; McGrath, J.; Seeburg, P.H.; Libermann, T.A.; Schlessinger, J.; Francke, U.; Levinson, A.; Ullrich, A. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science, 1985, 230(4730), 1132-1139.
80. Slamon, D.J.; Clark, G.M.; Wong, S.G.; Levin, W.J.; Ullrich, A.; McGuire, W.L. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 1987, 235(4785), 177-182.
81. Seshadri, R.; Firgaira, F.A.; Horsfall, D.J.; McCaul, K.; Setlur, V.; Kitchen, P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J. Clin. Oncol., 1993, 11(10), 1936-1942.
82. Slamon, D.J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; Baselga, J.; Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med., 2001, 344(11), 783-792.
83. Launay-Vacher, V.; Gligorov, J.; Le Tourneau, C.; Janus, N.; Spano, J.P.; Ray-Coquard, I.; Oudard, S.; Pourrat, X.; Morere, J.F.; Deray, G.; Beuzeboc, P. Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. Breast Cancer Res. Treat., 2010, 124(3), 745-753.
84. Zhu, X.; Wu, S.; Dahut, W.L.; Parikh, C.R. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am. J. Kidney Dis., 2007, 49(2), 186-193.
85. Gurevich, F.; Perazella, M.A. Renal effects of anti-angiogenesis therapy: Update for the internist. Am. J. Med., 2009, 122(4), 322-328.
86. Robinson, E.S.; Khankin, E.V.; Karumanchi, S.A.; Humphreys, B. D. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin. Nephrol., 2010, 30(6), 591-601.
87. Maynard, S.E.; Min, J.Y.; Merchan, J.; Lim, K.H.; Li, J.; Mondal S.; Libermann, T. A.; Morgan, J.P.; Sellke, F.W.; Stillman, I.E.; Epstein, F.H.; Sukhatme, V.P.; Karumanchi, S.A. Excess placental soluble fms-like tyrosine kinase 1(sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest., 2003, 111(5), 649-658.
88. Eremina, V.; Quaggin S. E. Biology of anti-angiogenic therapy-induced thrombotic microangiopathy. Semin. Nephrol., 2010, 30(6), 582-590.
89. Eremina, V.; Jefferson, J.A.; Kowalewska, J.; Hochster, H.; Haas, M.; Weisstuch, J.; Richardson, C.; Kopp, J.B.; Kabir, M.G.; Backx, P.H.; Gerber, H.P.; Ferrara, N.; Barisoni, L.; Alpers, C.E.; Quaggin S.E. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med., 2008, 358(11), 1129-1136.
90. Fukuoka, M.; Yano, S.; Giaccone, G.; Tamura, T.; Nakagawa, K.; Douillard, J.Y.; Nishiwaki, Y.; Vansteenkiste, J.; Kudoh, S.; Rischin, D.; Eek, R.; Horai, T.; Noda, K.; Takata, I.; Smit, E.; Averbuch, S.; Macleod, A.; Feyereislova, A.; Dong, R.P.; Baselga J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer(The IDEAL 1 Trial) [corrected]. J. Clin. Oncol., 2003, 21(12), 2237-2246.
91. Kris, M.G.; Natale, R.B.; Herbst, R.S.; Lynch, T.J.; Prager, D.; Belani, C.P.; Schiller, J.H.; Kelly, K.; Spiridonidis, H.; Sandler, A.; Albain K.S.; Cella, D.; Wolf, M.K.; Averbuch, S.D.; Ochs, J.J.; Kay, A.C. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA, 2003, 290(16), 2149-2158.
92. Mitsudomi, T.; Morita, S.; Yatabe, Y.; Negoro, S.; Okamoto, I.; Tsurutani, J.; Seto, T.; Satouchi, M.; Tada, H.; Hirashima, T.; Asami, K.; Katakami, N.; Takada, M.; Yoshioka, H.; Shibata, K.; Kudoh, S.; Shimizu, E.; Saito, H.; Toyooka, S.; Nakagawa, K.; Fukuoka, M. West Japan Oncology G. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor(WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol., 2010, 11(2), 121-128.
93. Velcheti, V.; Morgensztern, D.; Govindan, R. Management of patients with advanced non-small cell lung cancer: Role of gefitinib. Biologics, 2010, 4, 83-90.
94. Araki, T.; Yashima, H.; Shimizu, K.; Aomori, T.; Hashita, T.; Kaira, K.; Nakamura, T.; Yamamoto, K. Review of the treatment of non-small cell lung cancer with gefitinib. Clin. Med. Insights Oncol, 2012, 6, 407-421.
95. Kumasaka, R.; Nakamura, N.; Shirato, K.; Osawa, H.; Takanashi S.; Hasegawa, Y.; Yamabe, H.; Nakamura, M.; Tamura, M.; Okumura, K. Side effects of therapy: case 1. Nephrotic syndrome associated with gefitinib therapy. J. Clin. Oncol., 2004, 22(12), 2504-2505.
96. Wan, H.L.; Yao, N.S. Acute renal failure associated with gefitinib therapy. Lung, 2006, 184(4), 249-250.
97. Ringel, I.; Horwitz, S.B. Studies with RP 56976(taxotere): a semisynthetic analogue of taxol. J. Nat. Cancer Inst., 1991, 83(4), 288-291.
98. Rowinsky, E.K.; Donehower, R.C. Paclitaxel(taxol). N Engl.J. Med., 1995, 332(15), 1004-1014.
99. Jimenez, P.; Pathak, A.; Phan, A. T. The role of taxanes in the management of gastroesphageal cancer. J.Gastrointest. Oncol., 2011, 2(4), 240-249.
100. Takimoto, T.; Nakabori, T.; Osa, A.; Morita, S.; Terada, H.; Oseto, S.; Iwazawa, T.; Abe, K. Tubular nephrotoxicity induced by docetaxel in non-small-cell lung cancer patients. Int. J.Clin.Oncol., 2012, 17(4), 395-398.
101. Miller, R.P.; Tadagavadi, R.K.; Ramesh, G.; Reeves, W.B. Mechanisms of Cisplatin nephrotoxicity. Toxins(Basel), 2010, 2(11), 2490-2518.